# Tom Soloway

> Tom Soloway is the Chief Executive Officer of T-knife Therapeutics, a transatlantic biotech developing T-cell receptor (TCR-T) therapies aimed at solid tumors. With more than 25 years across strategy, operations, corporate finance and venture capital, he has helped build and finance a string of life sciences companies including Transcept Pharmaceuticals, Ascendis Pharma and Audentes Therapeutics. He took the helm of T-knife in January 2021, positioning the Berlin- and San Francisco-based company to move its 'supercharged' TCR-T candidates into the clinic while staying lean and capital-efficient.

- **Role:** Chief Executive Officer at T-knife Therapeutics
- **Organizations:** T-knife Therapeutics, Audentes Therapeutics, Ascendis Pharma A/S, Transcept Pharmaceuticals, Montreux Equity Partners, Third Harmonic Bio, Satsuma Pharmaceuticals
- **Nationality:** American
- **Education:** B.S. in Entrepreneurial Studies, University of Southern California, M.B.A. in Finance, Georgetown University McDonough School of Business
- **Known for:** Appointed CEO of T-knife Therapeutics in January 2021, leading a transatlantic TCR-T cell therapy company, Helped guide T-knife's $110M Series B financing (2021), Co-founded Transcept Pharmaceuticals and held CFO and COO roles there

## Career timeline

- **1990s** — Principal at Montreux Equity Partners, a healthcare and life sciences venture capital firm
- **2000s** — Co-founded Transcept Pharmaceuticals, serving as SVP Operations & CFO, then EVP & COO
- **2010s** — Senior Vice President and Chief Financial Officer of Ascendis Pharma A/S
- **2010s** — Executive Vice President and Chief Operating Officer of Audentes Therapeutics
- **2021** — Appointed Chief Executive Officer of T-knife Therapeutics (January 19, 2021)
- **2021** — T-knife closed a $110M Series B financing to advance TCR-T therapies for solid tumors
- **2025** — T-knife filed a clinical trial application for the Phase 1 ATLAS trial of TK-6302, a PRAME-targeted TCR-T therapy

## Achievements

- Appointed CEO of T-knife Therapeutics in January 2021, leading a transatlantic TCR-T cell therapy company
- Helped guide T-knife's $110M Series B financing (2021)
- Co-founded Transcept Pharmaceuticals and held CFO and COO roles there
- Served as CFO of Ascendis Pharma and COO of Audentes Therapeutics, both later high-profile biotech companies
- Advanced T-knife's lead candidate TK-6302 toward its first-in-human Phase 1 ATLAS trial (filed 2025)
- Served on the board of directors of Third Harmonic Bio

## Latest updates

- **2025-11** — T-knife filed a clinical trial application for the Phase 1 ATLAS trial of TK-6302, a PRAME-targeted 'supercharged' TCR-T therapy, with the trial expected to begin in the first half of 2026.
- **2025-10** — Soloway detailed T-knife's transatlantic, capital-efficient strategy and its 'supercharged' T-cell platform in a VC Magazin interview.

## Links

- Website: https://t-knife.com
- LinkedIn: http://www.linkedin.com/in/tom-soloway-a968434

---

Profile page: https://yespress.io/tom-soloway
Published by YesPress — https://yespress.io
Last updated: 2026-07-24